search
Back to results

Renal Sympathectomy in Treatment Resistant Essential Hypertension, a Sham Controlled Randomized Trial (ReSET)

Primary Purpose

Hypertension

Status
Completed
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Renal artery ablation
Renal angiography
Sponsored by
Aarhus University Hospital Skejby
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Treatment Resistant Hypertension

Eligibility Criteria

30 Years - 70 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Systolic daytime ambulatory BP at least 145 mmHg and compliance to a minimum of 3 antihypertensive drugs, including a diuretic, or in case of diuretic intolerance at least 3 nondiuretic antihypertensive drugs.

Exclusion Criteria:

  • Pregnancy
  • Non compliance
  • Heart Failure (NYHA 3-4)
  • LV ejection fraction < 50 %
  • Renal insufficiency (eGFR<30)
  • Unstable coronary heart disease
  • Coronary intervention within 6 months
  • Myocardial infarction within 6 months
  • Claudication
  • Orthostatic syncope within 6 months
  • Secondary Hypertension
  • Permanent atrial fibrillation
  • Significant Heart Valve Disease
  • Clinically Significant abnormal electrolytes, haemoglobin, Liver enzymes, TSH
  • Second and third degree heart block
  • Macroscopic haematuria
  • Proximal significant coronary stenosis
  • Renal artery anatomy not suitable for renal artery ablation (Stenosis, small diameter < 4 mm, length < 2 cm, multiple renal arteries, severe calcifications)

Sites / Locations

  • Skejby Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Sham Comparator

Arm Label

Renal artery ablation

Sham

Arm Description

By femoral access, coronary and renal angiography are performed. The patient will be sedated. In case of vessel anatomy allowing renal ablation, the patient will be randomized in the card. lab. In case of randomization to active treatment, renal artery ablation will be carried out straight away.

By femoral access, coronary and renal angiography are performed. The patient will be sedated. In case of vessel anatomy allowing renal ablation, the patient will be randomized in the card. lab. In case of randomization to sham procedure, no renal artery ablation are performed.

Outcomes

Primary Outcome Measures

daytime systolic blood pressure assessed by 24 hours ambulatory BP measurement
Changes in mean daytime systolic BP after 3 months is compared between groups. Also the proportion of responders versus nonresponders after 3 months is compared between groups, responders being defined as A) a minimum decrease in daytime systolic BP of 10 mmHg analysis together with and unchanged/increased number of antihypertensive drugs, or B) a decrease in daytime systolic BP of 0-10 mmHg together with a reduced number of antihypertensive drugs.

Secondary Outcome Measures

ambulatory 24 hours BP measurements
Systolic, diastolic and mean Blood Pressures at different time points. Daytime and night time BP, dipping status, morning BP surge and BP variation.
Echocardiography
Coronary flow reserve (LAD), Diastolic and Systolic ventricular function. LV hypertrophy.
Biomarkers
Biomarkers concerning renal sodium excretion
Applanation tonometry
Pulse wave velocity, augmentation index, central BP estimates
forearm plethysmography
Forearm minimum vascular resistance

Full Information

First Posted
October 24, 2011
Last Updated
September 19, 2016
Sponsor
Aarhus University Hospital Skejby
Collaborators
Aarhus University Hospital, Regionshospitalet Silkeborg, Randers Regional Hospital, Regional Hospital Holstebro, Central Jutland Regional Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT01459900
Brief Title
Renal Sympathectomy in Treatment Resistant Essential Hypertension, a Sham Controlled Randomized Trial
Acronym
ReSET
Official Title
Renal Sympathectomy in Treatment Resistant Essential Hypertension, a Sham Controlled Randomized Trial
Study Type
Interventional

2. Study Status

Record Verification Date
September 2016
Overall Recruitment Status
Completed
Study Start Date
September 2011 (undefined)
Primary Completion Date
February 2015 (Actual)
Study Completion Date
February 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Aarhus University Hospital Skejby
Collaborators
Aarhus University Hospital, Regionshospitalet Silkeborg, Randers Regional Hospital, Regional Hospital Holstebro, Central Jutland Regional Hospital

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The purpose of this double blind, randomized and sham controlled study is to determine whether renal denervation in terms of catheter based ablation in the renal arteries is effective in lowering blood pressure in patients with treatment resistant hypertension. The blood pressure lowering effect will be evaluated by 24 hours ambulatory blood pressure measurement at baseline and after 1, 3 and 6 months of follow up. Secondary end point evaluation concerns hemodynamic measures using echocardiography, applanation tonometry and forearm plethysmography.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Treatment Resistant Hypertension

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare Provider
Allocation
Randomized
Enrollment
69 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Renal artery ablation
Arm Type
Active Comparator
Arm Description
By femoral access, coronary and renal angiography are performed. The patient will be sedated. In case of vessel anatomy allowing renal ablation, the patient will be randomized in the card. lab. In case of randomization to active treatment, renal artery ablation will be carried out straight away.
Arm Title
Sham
Arm Type
Sham Comparator
Arm Description
By femoral access, coronary and renal angiography are performed. The patient will be sedated. In case of vessel anatomy allowing renal ablation, the patient will be randomized in the card. lab. In case of randomization to sham procedure, no renal artery ablation are performed.
Intervention Type
Procedure
Intervention Name(s)
Renal artery ablation
Intervention Description
Catheter based renal denervation by applying low power radiofrequency to the renal artery using the Ardian Medtronic Simplicity Catheter, introduced by femoral artery access.
Intervention Type
Procedure
Intervention Name(s)
Renal angiography
Intervention Description
Renal angiography by femoral access.
Primary Outcome Measure Information:
Title
daytime systolic blood pressure assessed by 24 hours ambulatory BP measurement
Description
Changes in mean daytime systolic BP after 3 months is compared between groups. Also the proportion of responders versus nonresponders after 3 months is compared between groups, responders being defined as A) a minimum decrease in daytime systolic BP of 10 mmHg analysis together with and unchanged/increased number of antihypertensive drugs, or B) a decrease in daytime systolic BP of 0-10 mmHg together with a reduced number of antihypertensive drugs.
Time Frame
3 months follow up
Secondary Outcome Measure Information:
Title
ambulatory 24 hours BP measurements
Description
Systolic, diastolic and mean Blood Pressures at different time points. Daytime and night time BP, dipping status, morning BP surge and BP variation.
Time Frame
1, 3 and 6 months
Title
Echocardiography
Description
Coronary flow reserve (LAD), Diastolic and Systolic ventricular function. LV hypertrophy.
Time Frame
6 months
Title
Biomarkers
Description
Biomarkers concerning renal sodium excretion
Time Frame
1 months
Title
Applanation tonometry
Description
Pulse wave velocity, augmentation index, central BP estimates
Time Frame
6 months
Title
forearm plethysmography
Description
Forearm minimum vascular resistance
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Systolic daytime ambulatory BP at least 145 mmHg and compliance to a minimum of 3 antihypertensive drugs, including a diuretic, or in case of diuretic intolerance at least 3 nondiuretic antihypertensive drugs. Exclusion Criteria: Pregnancy Non compliance Heart Failure (NYHA 3-4) LV ejection fraction < 50 % Renal insufficiency (eGFR<30) Unstable coronary heart disease Coronary intervention within 6 months Myocardial infarction within 6 months Claudication Orthostatic syncope within 6 months Secondary Hypertension Permanent atrial fibrillation Significant Heart Valve Disease Clinically Significant abnormal electrolytes, haemoglobin, Liver enzymes, TSH Second and third degree heart block Macroscopic haematuria Proximal significant coronary stenosis Renal artery anatomy not suitable for renal artery ablation (Stenosis, small diameter < 4 mm, length < 2 cm, multiple renal arteries, severe calcifications)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ole N Mathiassen, MD, PhD
Organizational Affiliation
Aarhus University Hospital, Dep. Cardiology
Official's Role
Principal Investigator
Facility Information:
Facility Name
Skejby Hospital
City
Aarhus
State/Province
Aarhus N
ZIP/Postal Code
8200
Country
Denmark

12. IPD Sharing Statement

Citations:
PubMed Identifier
28830251
Citation
Peters CD, Mathiassen ON, Vase H, Bech Norgaard J, Christensen KL, Schroeder AP, Rickers HJVH, Opstrup UK, Poulsen PL, Langfeldt S, Andersen G, Hansen KW, Botker HE, Engholm M, Bertelsen JB, Pedersen EB, Kaltoft A, Buus NH. The effect of renal denervation on arterial stiffness, central blood pressure and heart rate variability in treatment resistant essential hypertension: a substudy of a randomized sham-controlled double-blinded trial (the ReSET trial). Blood Press. 2017 Dec;26(6):366-380. doi: 10.1080/08037051.2017.1368368. Epub 2017 Aug 23.
Results Reference
derived

Learn more about this trial

Renal Sympathectomy in Treatment Resistant Essential Hypertension, a Sham Controlled Randomized Trial

We'll reach out to this number within 24 hrs